Global Stable Isotope Labelled Compounds Market is expected to grow at a CAGR of 3.0% during the forecast period 2020-2027
A new research report published by Fior Markets with the title Stable Isotope Labelled Compounds Market by Application (Clinical Diagnostics, Industrial, Research), By Type (Oxygen 18, Carbon 13, H-2, D, N15), by End-user (Academic institute, Pharmaceutical & Biopharmaceutical Companies), Regions, and Global Forecast 2020-2027.
The global stable isotope labelled compounds market is expected to grow from USD 369.00 million in 2019 to USD 340.76 million by 2027, at a CAGR of 3.0% during the forecast period 2020-2027. North America is anticipated to dominate the market, followed by Europe. The market growth in these regions is due to support from isotope production and distribution program fund, presence of large nuclear industry, and the growing pharmaceutical and biopharmaceutical industry. Developed countries are also anticipated to fuel the market. Countries like Canada have surging demand for stable isotope labelled compounds, propped by advances made in positron emission tomography technique.
DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/418403/request-sample
Some of the key players in the market are Omicron Biochemicals Inc., IsoSciences, Cambridge Isotopes Laboratories Inc., Nordion, Merck KGaA, and LLC.
The application segment includes clinical diagnostics, industrial research. The research segment is anticipated to witness the largest share in the market, due to increasing research activities in pharmaceuticals, biomedical, agricultural, environmental and ecological sectors. Based on type, the market is segmented into oxygen 18, carbon 13, H-2, D, and N15. The H-2 segment is expected to show a significant growth in the market, due to the growing nuclear industry and an increasing pharmaceutical research conducted using deuterium. Growing drug research in the pharmaceutical industry and the growing availability of deuterium-labelled compounds drives the market. Based on end-user, the market is segmented into the academic institute, pharmaceutical & biopharmaceutical companies. The pharmaceutical & biopharmaceutical companies segment holds the largest share in the market, owing to increased R&D spending. This drives the drug research activities in the industry.
The factors driving the market are increasing prevalence of cancer, an increase in research activities in the pharmaceutical and biotechnology sector, the rise in various drug toxicity and rise in proteomics research. Factors hampering the market growth is the rising cost of stable isotope labelled compounds. The opportunities for the market growth are mortality in paediatric populations and the rising focus on accelerating the validation of new treatment modalities in order to reduce morbidity. Thus, the market is expected to show a significant growth.
About the report:
The global stable isotope labelled compounds market is analyzed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.
Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on firstname.lastname@example.org or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.
- CDN Newswire